Selecta Biosciences, Inc. (NASDAQ:SELB) has been assigned an average recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $27.75.
A number of equities research analysts have recently weighed in on SELB shares. ValuEngine upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 30th. Zacks Investment Research upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Canaccord Genuity set a $25.00 price target on Selecta Biosciences and gave the company a “buy” rating in a report on Wednesday, July 26th.
WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/selecta-biosciences-inc-selb-given-consensus-rating-of-hold-by-brokerages/1699982.html.
In related news, Director Amir Nashat sold 147,187 shares of the company’s stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $19.91, for a total transaction of $2,930,493.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David Siewers sold 16,424 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total value of $328,480.00. Following the transaction, the chief financial officer now owns 2,194 shares of the company’s stock, valued at $43,880. The disclosure for this sale can be found here. Insiders sold a total of 355,658 shares of company stock valued at $6,955,732 over the last quarter. Company insiders own 41.90% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vivo Capital LLC bought a new position in Selecta Biosciences during the 2nd quarter worth $22,227,000. JPMorgan Chase & Co. grew its stake in Selecta Biosciences by 46.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 358,846 shares of the company’s stock worth $7,126,000 after buying an additional 114,477 shares during the last quarter. Vanguard Group Inc. grew its stake in Selecta Biosciences by 175.5% during the 2nd quarter. Vanguard Group Inc. now owns 217,634 shares of the company’s stock worth $4,322,000 after buying an additional 138,646 shares during the last quarter. State Street Corp grew its stake in Selecta Biosciences by 118.5% during the 2nd quarter. State Street Corp now owns 152,430 shares of the company’s stock worth $3,027,000 after buying an additional 82,665 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its stake in Selecta Biosciences by 306.5% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 126,000 shares of the company’s stock worth $2,502,000 after buying an additional 95,000 shares during the last quarter. Hedge funds and other institutional investors own 53.53% of the company’s stock.
Selecta Biosciences (NASDAQ:SELB) traded down 0.10% during midday trading on Friday, hitting $19.75. The stock had a trading volume of 62,472 shares. Selecta Biosciences has a 12-month low of $10.27 and a 12-month high of $28.00. The company has a 50-day moving average price of $18.81 and a 200-day moving average price of $18.81. The company’s market cap is $435.96 million.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.01. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. The business had revenue of $0.03 million during the quarter. Equities analysts anticipate that Selecta Biosciences will post ($3.17) EPS for the current year.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with our FREE daily email newsletter.